NCT05741424 - Impact of BacT/Alert® VIRTUO®, BioFire® Blood Culture Identification 2-BCID2 and REVEAL® (bioMérieux) on the Optimization of Antibiotic Therapy for Gram-negative Bacteremia in the ICU | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

May 6, 2024

Study Completion Date

June 16, 2024

Conditions

Bacteremia

Interventions

DIAGNOSTIC_TEST

Innovative diagnostic technologies

Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions

DIAGNOSTIC_TEST

Reference diagnostic technique

Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.

Trial Locations (1)

Unknown

CHU de Nîmes, Nîmes